This study investigates CEA-positive advanced solid tumors. The purpose of this study is to evaluate the safety and effectiveness of the investigational CAR-T cell therapy.
The study focuses on assessing how well the investigational treatment works and how safe it is for patients with CEA-positive advanced solid tumors.
- Who can participate: Adults aged 18 and older with advanced or recurrent malignant tumors, such as colorectal or pancreatic cancer, who have failed at least second-line standard treatments and have CEA-positive tumors may participate.
- Study details: Participants will receive CAR-T cell therapy through either intravenous or local infusion. Some may receive a placebo, which is an inactive substance that looks like the investigational medicine but does not contain any medicine.
How understandable was the trial content above?
Hard to understand
Easy to understand